We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
Read MoreHide Full Article
Shares of Vaxart, Inc. (VXRT - Free Report) were up 8.8% on Tuesday after the company announced that it has dosed the first subject in a phase I study, evaluating its oral tablet VXA-CoV2-1, which is a COVID-19 vaccine candidate.
In fact, the stock has skyrocketed 2088.3% so far this year against the industry’s decrease of 4.1%.
The early-stage dose-ranging study is evaluating the safety and immunogenicity of two doses (low or high) of the oral tablet VXA-CoV2-1 in healthy adult volunteers, aged between 18 years and 54 years. Enrollment in the same is expected to be completed by early next month. The first clinical data from the study is anticipated shortly in the coming weeks
Pre-clinical data had shown that the vaccine was able to generate both immune responses as well as a strong mucosal immune response against SARS-CoV-2, the virus that causes COVID-19.
Last month, the FDA cleared Vaxart’s investigational new drug (IND) application to begin the phase I study. The primary goal of the study is to investigate the safety and reactogenicity of two doses of the said vaccine. Secondary objectives include immunogenicity, duration of immune response and the occurrence of the symptomatic COVID-19.
Notably, the oral vaccine candidate is being developed leveraging the company’s proprietary oral vaccine platform VAAST.
Vaxart’s COVID-19 candidate is the only oral vaccine to be selected as part of the U.S. government’s Operation Warp Speed (OWS) program, which is a new national program to provide substantial quantities of safe, effective vaccine for the Americans by January 2021.
We note that several drugmakers are working relentlessly to develop a vaccine for the deadly coronavirus disease, which has so far infected 38.1 million people globally and killed more than a million already.
Small biotechs like Moderna (MRNA - Free Report) , CureVac (CVAC - Free Report) and Novavax (NVAX - Free Report) along with large pharma companies, namely AstraZeneca, Johnson & Johnson and Pfizer among others are actively engaged in developing a vaccine to fight the COVID-19 pandemic.
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits. The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Image: Bigstock
Vaxart (VXRT) Begins Dosing in Oral Coronavirus Vaccine Study
Shares of Vaxart, Inc. (VXRT - Free Report) were up 8.8% on Tuesday after the company announced that it has dosed the first subject in a phase I study, evaluating its oral tablet VXA-CoV2-1, which is a COVID-19 vaccine candidate.
In fact, the stock has skyrocketed 2088.3% so far this year against the industry’s decrease of 4.1%.
The early-stage dose-ranging study is evaluating the safety and immunogenicity of two doses (low or high) of the oral tablet VXA-CoV2-1 in healthy adult volunteers, aged between 18 years and 54 years. Enrollment in the same is expected to be completed by early next month. The first clinical data from the study is anticipated shortly in the coming weeks
Pre-clinical data had shown that the vaccine was able to generate both immune responses as well as a strong mucosal immune response against SARS-CoV-2, the virus that causes COVID-19.
Last month, the FDA cleared Vaxart’s investigational new drug (IND) application to begin the phase I study. The primary goal of the study is to investigate the safety and reactogenicity of two doses of the said vaccine. Secondary objectives include immunogenicity, duration of immune response and the occurrence of the symptomatic COVID-19.
Notably, the oral vaccine candidate is being developed leveraging the company’s proprietary oral vaccine platform VAAST.
Vaxart’s COVID-19 candidate is the only oral vaccine to be selected as part of the U.S. government’s Operation Warp Speed (OWS) program, which is a new national program to provide substantial quantities of safe, effective vaccine for the Americans by January 2021.
We note that several drugmakers are working relentlessly to develop a vaccine for the deadly coronavirus disease, which has so far infected 38.1 million people globally and killed more than a million already.
Small biotechs like Moderna (MRNA - Free Report) , CureVac (CVAC - Free Report) and Novavax (NVAX - Free Report) along with large pharma companies, namely AstraZeneca, Johnson & Johnson and Pfizer among others are actively engaged in developing a vaccine to fight the COVID-19 pandemic.
Zacks Rank
Vaxart currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Have You Seen Zacks’ 2020 Election Stock Report?
The upcoming election could be a massive buying opportunity for savvy investors. Trillions of dollars will shift into new market sectors after the election. The question is, which sectors will soar for each candidate? Zacks has put together a new special report to help readers like you target big profits.
The 2020 Election Stock Report reveals specific stocks you’ll want to own immediately after the results are announced – 6 if Trump wins, 6 if Biden wins. Past election reports have led investors to gains of +71%, +83%, even +185% in the following months. This year’s picks could be even more lucrative.
Check out Zacks’ 2020 Election Stock Report >>